drugset / Trial / NCT05402384
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
Phase 2
Not yet recruiting
10 enrolled
Eva Morava-Kozicz
Children's Hospital of Philadelphia · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collabRare Diseases Clinical Research Network · collab
RandomizedCrossoverTriple-blindTreatment
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, cross-over study to evaluate the efficacy and safety of AVTX-801 in subjects with SLC35A2-CDG
Timeline
- Start
- 2027-01
- Primary completion
- 2028-03
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galactose | Diagnostic / imaging agent | 2 g/kg | — |